TLDR The research found a link between certain molecular features and the biological activity of BC3, which can help identify or create new active compounds.
In 2004, a study was conducted on a set of 41 benzo[c]quinolizin-3-ones (BC3), some of which were explored as selective inhibitors of the human 5α-reductase steroid. The researchers divided the molecules into groups of tested and untested compounds for the structure-activity study. They used semiempirical calculations and pattern recognition methods such as Electronic Indices Methodology (EIM), Principal Components Analysis (PCA), Hierarchical Cluster Analysis (HCA), and K−Nearest Neighbors (KNN) to find a correlation between experimental activity and theoretical descriptors. The results showed that it was possible to directly correlate some molecular quantum descriptors with BC3 biological activity. This information could be used to identify active/inactive untested compounds and/or to design new active compounds.
![Benzo[c]quinolizin-3-ones: A Novel Class of Potent and Selective Nonsteroidal Inhibitors of Human Steroid 5α-Reductase 1](/images/research/ff6e6cbe-cb9c-4d11-87ef-671d28ffd4fa/small/15506.jpg)
28 citations,
September 2000 in “Journal of Medicinal Chemistry” Benzo[c]quinolizin-3-ones are effective nonsteroidal inhibitors of human steroid 5α-reductase 1.
45 citations,
September 2000 in “Archives of dermatology” The study found that the enzyme linked to acne is present in the same areas of both acne-affected and normal skin.
5 citations,
July 2000 in “Southern Medical Journal” Male pattern baldness is often genetic and linked to a hormone, with treatments like finasteride and minoxidil being effective for some men.
70 citations,
June 1993 in “Biochemistry” Finasteride slowly binds to 5-alpha-reductase, affecting enzyme stability and inhibitor potency.
53 citations,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
89 citations,
February 1993 in “Journal of Medicinal Chemistry” New compounds called benzoquinolinones may treat conditions linked to excess DHT.
![Effect of C-Ring Modifications in Benzo[c]quinolizin-3-ones, New Selective Inhibitors of Human 5α-Reductase 1](/images/research/c687900f-ea40-4de1-8f0b-a5b818951b1c/small/15452.jpg)
12 citations,
June 2001 in “Bioorganic & Medicinal Chemistry” Changing the C-ring structure in certain compounds can make them better at blocking a specific human enzyme.
6 citations,
August 2009 in “Mini-reviews in Medicinal Chemistry” Different drugs can treat high male hormone levels in women, but they have various effects and some may harm a fetus.
![Synthesis and Activity of 8-Substituted Benzo[c]quinolizin-3-ones as Dual Inhibitors of Human 5α-Reductases 1 and 2](/images/research/efc54340-66d6-4f27-9930-045ac023f903/small/15248.jpg)
9 citations,
November 2004 in “Bioorganic & Medicinal Chemistry Letters” New compounds were made that effectively block enzymes related to prostate issues and hair loss.
49 citations,
January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology” Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.
17 citations,
May 1998 in “Steroids” Researchers developed a model to predict how well certain compounds can block an enzyme related to hair loss and prostate issues, suggesting a 50 mg dose of finasteride might be effective based on lab and body data.
